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Abstract
Objective. To determine recent trends in the rate and management of new cases of OA presenting to
primary healthcare using UK nationally representative data.
Methods. Using the Clinical Practice Research Datalink we identified new cases of diagnosed OA and
clinical OA (including OA-relevant peripheral joint pain in those aged over 45 years) using established code
lists. For both definitions we estimated annual incidence density using exact person-time, and undertook
descriptive analysis and age-period-cohort modelling. Demographic characteristics and management
were described for incident cases in each calendar year. Sensitivity analyses explored the robustness
of the findings to key assumptions.
Results. Between 1992 and 2013 the annual age-sex standardized incidence rate for clinical OA
increased from 29.2 to 40.5/1000 person-years. After controlling for period effects, the consultation inci-
dence of clinical OA was higher for successive cohorts born after the mid-1950s, particularly women. In
contrast, with the exception of hand OA, we observed no increase in the incidence of diagnosed OA: 8.6/
1000 person-years in 2004 down to 6.3 in 2013. In 2013, 16.4% of clinical OA cases had an X-ray referral.
While NSAID prescriptions fell from 2004, the proportion prescribed opioid analgesia rose markedly (0.1%
of diagnosed OA in 1992 to 1.9% in 2013).
Conclusion. Rising rates of clinical OA, continued use of plain radiography and a shift towards opioid
analgesic prescription are concerning. Our findings support the search for policies to tackle this common
problem that promote joint pain prevention while avoiding excessive and inappropriate health care.
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Rheumatology key messages
. Incidence of OA presenting and diagnosed in UK primary care has not risen.
. New presentations of joint-pain are increasing among younger OA cohorts.
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Introduction
Dramatic increases over the past two decades have been
reported in the population burden and healthcare demand
associated with OA. The Global Burden of Disease project
recently estimated that crude disability-adjusted life-years
attributed to OA increased by 34% between 1990 and
2015, among the largest increases seen for any non-
communicable disease [1]. Within the same period, data
available from many high-income countries show signifi-
cant increases in the numbers and rates of primary hip
and knee arthroplasty [26], over 90% of which are per-
formed for OA [7]. Total direct and indirect costs asso-
ciated with OA are now conservatively estimated at
0.250.50% gross domestic product in high-income
countries [8, 9].
The rate of new cases of symptomatic OA arising in the
population provides crucial information for health-policy
makers, responding more quickly to changes in risk fac-
tors and being less influenced by disease duration.
However, obtaining reliable incidence estimates for OA
in general population cohort studies is challenging and
the Global Burden of Disease project found previous es-
timates to be scarce and unusable [10]. As primary care is
the first point of contact with formal healthcare services,
the rate of new cases presenting and recorded in this
setting (consultation incidence) provides one of the few
continuous, ongoing sources of data with which to evalu-
ate trends over time in the incidence of OA, albeit subject
to the prevailing propensity to consult primary healthcare
and coding systems and behaviour. To date, only two
published studies worldwide, both using the same subna-
tional administrative healthcare database in British
Columbia, have estimated trends in the incidence of OA
[11, 12]. These showed annual increases in crude OA in-
cidence rates averaging 1.33.3% between 199697 and
200809, dropping to <1% per year after age-standard-
ization. In the UK, we found an increase in OA consultation
incidence between 2003 and 2010 among 3544 year olds
but based on small numbers within a regional network of
general practices [13].
Our study sought to provide the first national and sub-
national estimates of trends in the consultation incidence
of OA and patterns of initial management between 1992
and 2013 in the UK using a large nationally representative
primary care database.
Methods
Study design and setting
We undertook a descriptive study using routinely col-
lected longitudinal data from the UK Clinical Practice
Research Datalink (CPRD), which contains computerized
primary care records from general practices covering
around 7% of the UK population [14]. CPRD records
anonymized patient demographics, consultations, diag-
noses, prescriptions and tests from primary care, and
also includes those referrals to specialists, hospital admis-
sions and diagnoses made in secondary care, reported
back to the general practitioners and recorded by them
within their computerized records. CPRD has reported
high validity for a range of diagnoses [15]. The study
was approved by the independent scientific advisory
committee for CPRD research (protocol reference:
14_09010_193 R). No further ethical permissions were
required for the analyses of these anonymized patient
level data.
Definition of incident cases and at-risk population
Several algorithms have been used in previous studies,
predominantly from Canada and the USA, to define OA
cases in electronic health record and administrative data-
bases [16, 17]. In line with a Swedish report [18], we chose
case definitions requiring a single record of a relevant
code within the primary care electronic health record
within a calendar year of interest. Less restrictive defin-
itions such as these have been used in previous studies of
OA incidence in Canada [11, 12, 19, 20], the Netherlands
[2123] and Spain [24], and of OA consultation prevalence
in UK primary care [25, 26] and have generally higher sen-
sitivity but lower specificity than more restrictive algo-
rithms requiring multiple records [17].
Using established Read code lists [26] (code lists avail-
able from www.keele.ac.uk/mrr) we defined cases of OA
in two ways: firstly, to maximize sensitivity and capture the
greatest number of new consulting cases of OA, cases
were defined as having either at least one consultation
with a recorded diagnosis of OA or, in adults aged over
45 years, at least one consultation with a recorded periph-
eral joint pain symptom code affecting the knee, hip and
hand/wrist likely to reflect OA (clinical OA); secondly,
cases of OA were defined more narrowly as having at
least one consultation with a recorded diagnosis of OA
(OA). We excluded cases with a record of a systemic in-
flammatory disease, spondyloarthropathy or crystal dis-
ease in the previous 3 years or following 1 year, or a
record of another specific non-OA diagnosis (soft-tissue
disorders, other bone/cartilage diseases) at the same joint
in the 6 months before or after the recorded OA/joint pain
consultation.
The at-risk population in each calendar year was
defined as all patients with complete registration history
within CPRD in the previous 3 calendar years and no OA
consultation in that period. Incident cases among the at-
risk population in each calendar year were defined as a
coded record during the year (supplementary Fig. S1,
available at Rheumatology Online).
Descriptive characteristics and management of inci-
dent cases
To explore the changing characteristics of incident cases
of OA and their pharmacological management we
described the age and gender distribution of cases, and
the proportion of cases with:55 and510 British National
Formulary chapters prescribed in the 1 year prior to the
diagnosis date (a measure of multimorbidity) [27]; a record
of an X-ray referral within 30 days before or after diagnosis
date; a prescription for an NSAID, cyclooxygenase-2
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(COX-2) inhibitor, or opioid analgesic within 14 days after
diagnosis date. Opioid analgesics were sub-classified into
weak (e.g. codeine 8 mg + paracetamol), moderate (e.g.
dihydrocodeine 20 mg), strong (e.g. tramadol 50 mg) and
very strong (e.g. oxycodone) [28].
Statistical analysis
Patients consulting for OA in a given year will be a mixture
of new (incident) cases and ongoing (prevalent) cases.
We used the run-in period method to look back in the
medical record to exclude prevalent cases and to define
the at-risk population. Run-in periods from 1 to 10 years
were compared using time series models and 3 years was
selected as optimal in this data source for OA [13]. Annual
crude incidence was defined by incidence density as the
number of incident cases divided by observed person-
time in each calendar year with persons censored by
death, moving practice, or OA diagnosis (supplementary
Fig. S1 and supplementary Table S1, available at
Rheumatology Online). Annual incidence was stratified
by gender, age group (3544, 4554, 5564, 6574,
7584, 85+ years) and geographical region. Agesex-
standardized incidence rates were estimated using the
mid-2013 UK population as the standard (supplementary
Methods, available at Rheumatology Online) with 95% CIs
estimated by Poisson regression. We estimated the total
numbers of newly diagnosed cases of OA and clinical OA
presenting to UK primary care in 2013 by multiplying the
incidence rates in 2013 from this study and estimated size
of the at-risk population in the UK in 2013 based on mid-
2013 population size and 6.9% population coverage by
CPRD in the same year [14].
To explore age-period-cohort effects, we first described
and plotted the age-stratified incidence of clinical OA in 14
birth cohorts: cohort-1915, cohort-1920, cohort-1925,
cohort-1930, cohort-1935, cohort-1940, cohort-1945,
cohort-1950, cohort-1955, cohort-1960, cohort-1965,
cohort-1970 and cohort-1975. We then modelled age-
period-cohort effects (in calendar years) on clinical OA
and OA from 1992 to 2013. Two approaches to age-
period-cohort analysis were used to provide a robust
check on results. OA and clinical OA incidence rates
were estimated using parametric smooth functions
based on natural cubic splines with knots each for age,
period and cohort variables to detect nonlinear effects
[29]. In the analysis of period effect, the calendar year of
2000 was used as the period referent group.
Sensitivity analyses
Incidence estimates are sensitive to the length of run-in
period [20, 30] and so we repeated the analyses using a
10 year run-in period [20]. General practice membership of
CPRD is dynamic (i.e. open to practices joining and leav-
ing) and so to evaluate the potential impact of this, we
estimated the incidence in four fixed practice cohorts
that joined at different periods but contributed continu-
ously thereafter to 2013: cohort 1 (102 practices providing
incidence estimates from 1994 to 2013), cohort 2 (73 prac-
tices, 200013), cohort 3 (163 practices, 200413), cohort
4 (130 practices, 200913) (supplementary Table S2,
available at Rheumatology Online). Data management
and analysis were performed using Stata MP Software
V14.1 (StataCorp, College Station, TX, USA).
Results
We analysed 1 716 253 incident cases of clinical OA and
432 163 incident cases of OA recorded between 1992 and
2013. In 2013, agesex standardized incidence rates for
clinical OA and OA were 40.5 (95% CI: 40.3, 40.7) and 6.3
(95% CI: 6.2, 6.4) per 1000 person-years, respectively.
For both case definitions, age-standardized incidence
rates were higher among women than men [46.2 (45.9,
46.5) vs 35.0 (34.7, 35.3) and 7.6 (7.5, 7.7) vs 4.9 (4.8,
5.0)], and peaked at 7584 years in women and in men.
The mean age of incident cases of clinical OA was
52.7 years (56.1% women) compared with 67.2 years
(61.6% women) among incident cases of OA. A record
of an X-ray referral at time of diagnosis was found in
16.4% of clinical OA cases and 22.0% of incidence OA
cases. Multimorbidity was common, with 51.0% of inci-
dent cases of clinical OA and 74.9% of OA cases pre-
scribed 55 unique categories of drug in the preceding
year (510 drug categories: 22.5% and 40.2%,
respectively).
Joint-specific standardized incidence estimates in 2013
for knee OA were as follows: clinical knee OA: 19.7 (over-
all), 20.8 (women), 18.5 (men); knee OA: 1.9, 2.1, 1.6; clin-
ical hip OA: 8.0, 10.4, 5.5; hip OA: 1.3, 1.6, 0.9; clinical
hand OA: 4.3, 5.2, 3.3; hand OA: 2.5, 3.5, 1.5. Similar pat-
terns of age-specific incidence were found for clinical knee
OA, knee OA, clinical hip OA and hip OA: a progressive
increase from age 3544 years, peaking at 7584 years in
men and women. A different age-specific pattern was
observed for clinical hand OA and hand OA, which
showed an early peak in age group 5564 years in women.
Temporal trend in OA incidence and management,
19922013: descriptive analyses
Annual agesex standardized incidence rates of diag-
nosed OA showed a small increase over the period
19922004 but decreased thereafter (Table 1). The
annual standardized incidence rates of clinical OA were
also largely stable from 1992 to 2000 but then increased
markedly to 2009 after which they dropped slightly.
Similar trends for both case definitions were observed in
women and men and in each age stratum (Fig. 1).
The trends of clinical OA and OA incidence rates dif-
fered by joint. In keeping with the trend seen for clinical
OA in general, both clinical knee OA and clinical hip OA
increased markedly from 2000 reaching a plateau in
200913 whereas clinical hand OA increased steadily
from 2000 to 2013. Knee OA and hip OA remained rela-
tively stable from 2000 to 2013, while hand OA increased
steadily over the same period (supplementary Table S3
and supplementary Fig. S2, available at Rheumatology
Online). The fluctuating incidence of hip OA and hand
OA we interpret as reflecting variable use joint-specific
OA codes before 2000.
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The increase in incidence of clinical OA between 2000
and 2009 was more marked in regions with comparatively
low incidence rates in 2000, such that regional variation
was reduced in 2009 (Fig. 2; supplementary Fig. S3, avail-
able at Rheumatology Online).
In our sensitivity analyses, similar trends of incidence
rates for both clinical OA and OA were observed when
the run-in period was extended to 10 years (supplemen-
tary Fig. S4, available at Rheumatology Online), but with
lower incidence for clinical OA suggesting that a run-in
period longer than 3 years is needed to identify first con-
sultation for this case definition (clinical OA: 32.9/1000
person-years; OA: 6.6/1000 person-years, in 2013).
Based on this conservative 10-year run-in period, we es-
timate that in 2013 approximately 1 209 594 new cases of
clinical OA presented to UK primary care, of whom
432 804 received the diagnosis of OA. A similar trend in
incidence rate was also identified when analysis was re-
stricted to the four fixed cohorts of practices who contrib-
uted to incidence estimates continuously from joining to
2013 (supplementary Fig. S5, available at Rheumatology
Online).
Temporal trend in OA incidence, 19922013: age-
period-cohort analyses
Figure 3 (supplementary Fig. S6, available at Rheumatology
Online) shows plots of clinical OA and OA incidence by age
for the six selected birth cohorts. At virtually every age, later
birth cohorts had higher rates of incidence of clinical OA
than earlier birth cohorts. Cohorts born after the mid-
1950s showed an increased incidence of clinical OA par-
ticularly in females while a decline in the incidence of OA
was seen (Fig. 4; supplementary Fig. S7, available at
Rheumatology Online).
Trends in characteristics and prescribed analgesia
among incident cases of OA, 19922013
All forms of analgesia were more likely to be prescribed to
incident cases of OA than cases with clinical OA. Cox-2
prescriptions among incident cases increased in
19992004 and declined sharply afterwards (coinciding
with withdrawal of rofecoxib [31] and safety advice on all
selective Cox-2 inhibitors issued by the Medicines &
Healthcare Products Regulatory Agency [32]). The propor-
tion of incident cases receiving a prescription for oral
NSAID also declined after 2004 with weak combination
opioids becoming the most common class of prescribed
analgesia from 2005 onwards. The proportion of incident
cases of OA receiving a prescription for very strong
opioids increased from 0.1% in 2004 to 0.5% in 2013
for clinical OA; 0.6% in 2006 to 1.2% in 2013 for OA
(Table 2).
FIG. 1 Age-specific temporal trend in incidence rate of OA, by gender: UK, 19922013
Solid line and dotted line represent the incidence rates for clinical OA and OA, respectively. Light grey triangle, dark grey
diamond and black circle indicate estimates for women, men and all, respectively.
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FIG. 2 Region-specific temporal trend in incidence rate of OA, by gender: UK, 19922013
Left panel: clinical OA; right panel: OA. In each plot, the black line represents the trend of overall incidence in the specific
region; the grey line represents the general trend of overall incidence in the UK; the bubble size in each calendar year is
determined by the proportion of the overall at-risk population within that region.
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Discussion
OA is a significant and growing problem worldwide
whether measured in terms of population burden or joint
arthroplasty procedures. Primary care occupies a critical
role in the response of healthcare systems to this public
health challenge [33]. Our UK national study found that the
incidence of clinical OA presenting to primary care—mea-
sured broadly as new cases of diagnosed OA and periph-
eral joint pain in patients aged over 45 years—increased
between 1992 and 2013, reaching 40.5/1000 person-
years in 2013. The majority of this increase was seen be-
tween 2000 and 2009 and affected all ages, birth cohorts
and geographical regions, particularly those regions with
the lowest rates before 2000. Beyond this strong period
effect, however, we saw a continued increase in the con-
sultation incidence of clinical OA for successive cohorts
born after the mid-1950s, particularly women. In contrast,
with the exception of hand OA, we observed no increase
in the annual incidence of diagnosed cases of OA over the
same period. Instead, rates declined from a high of 8.6/
1000 person-years in 2004 to 6.3 in 2013.
Age-standardized incidence rates for physician-diag-
nosed OA reported in previous studies of health adminis-
trative and primary care electronic health record data in
Canada [11, 12, 19, 20, 30], the Netherlands [2123] and
the UK [13] range between 5 and 17 cases per 1000
person-years. It is well-recognized that such rates are
sensitive to the specific case definition adopted, the
length of run-in period used to exclude prevalent cases,
the capture and linkage of hospital data and other data-
bases, population structure and the particular character-
istics and incentives for coding behavior within different
healthcare systems and databases. Against previously re-
ported incidence rates, those in the current study for diag-
nosed OA in CPRD are comparatively low, something we
also observed for estimates of consultation prevalence of
musculoskeletal disorders [25]. It is notable that the aver-
age age at diagnosis of OA was 67.2 years in 2013—only 1
or 2 years less than the mean age of patients undergoing
primary hip or knee arthroplasty for OA in the UK [34].
Attending only to consultations recorded with the diag-
nostic code of OA may therefore provide a late and partial
view of demand for primary care in the UK. Incidence rate
estimates for clinical OA are substantially higher, required
a longer run-in period to exclude prevalent cases, showed
stronger period effects, and most likely represent the
upper limits of new cases of OA presenting to primary
care. Importantly, observed trends in incidence rates of
OA and clinical OA in the current study were not sensitive
to the length of run-in period or to the dynamic nature of
practice membership within CPRD over time.
An increasing incidence of clinical OA among recent
birth cohorts is consistent with similar trends in obesity
[35, 36]—a potent risk factor for OA [37, 38]—and the
increased reporting and presentation of painful symptoms
in general. In contrast, the relative stability of diagnosed
OA rates argues against there having been major changes
in the incidence of more severe OA in recent decades. In
one of the few population-based studies of changes in the
prevalence of knee OA symptoms and radiographic
changes in the USA, Nguyen et al. [39] found substantial
increases in self-reported knee pain but not radiographic
OA between 1974 and 1994 after adjusting for changing
distribution of BMI. Nevertheless, the observed trend of
increasing incidence of clinical OA in recent birth cohorts
may translate into future increased demand for joint
arthroplasty beyond that driven by demographic change,
and in the context of changing indications of the propor-
tion of all clinical OA who may benefit from surgery or be
referred for this.
The rising use of prescribed opioid analgesia is not lim-
ited to OA but has been previously highlighted in the UK
and other high-income countries [28, 4044]. This trend
FIG. 2 Continued
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FIG. 3 Age-specific incidence rate of OA, by selected birth cohorts: UK, 19922013
Left panel: clinical OA; right panel: OA. Small circle indicates the birth cohort 1925; small open triangle indicates the birth
cohort 1935; small open circle indicates the births cohort 1945; plus symbol indicates the birth cohort 1955; large solid
triangle indicates the birth cohort 1965; large solid circle indicates the birth cohort 1975.
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needs to be seen also in the context of rising levels of
multimorbidity and co-pharmacy among cases of OA.
We found that new cases of OA will often have multiple
different prescribed medicines. While the definition used
in our study could include short-term prescriptions and
different analgesic prescriptions, nevertheless we inter-
pret these data as consistent with the findings of Melzer
et al. [45] who reported high and rising prevalence of poly-
pharmacy and multimorbidity in patients aged >65 years,
and particularly aged >85 years in the period 200304 to
201112. This trend is likely to present increasing chal-
lenges for the selection and use of pharmacological,
non-pharmacological and surgical treatments for OA.
The temporal pattern of paracetamol use was not pre-
sented in this study because a large fraction of paraceta-
mol use would be from over-the-counter supply and the
prescribed supply would largely reflect the age of exemp-
tion from prescription costs. Less well-documented is the
continued high use of radiographic investigations despite
guidelines over the past two decades consistently high-
lighting their limited role in the assessment and diagnosis
of OA [4648]. Utilization of MRI to aid OA diagnosis was
not part of our original protocol submitted to, and
approved, by the Independent Scientific Advisory
Committee: the validity of coding MRI has yet to be inves-
tigated in CPRD and this is perhaps a future study. We
also refrained from analysing the temporal pattern of BMI
among incident cases, because in CPRD, the complete-
ness of BMI changed over time, that is, 37% in 199094
and 77% in 200511, and varied by female and age
(higher in female gender and increased with age) [14].
The trend of BMI/obesity among incident OA cases
would be significantly affected by the completeness of
BMI, which is almost certainly missing not at random
(i.e. the reason for not having a recorded BMI is related
to your BMI; for example, only people who are overweight
or have some other risk factors or health conditions will
have their BMI recorded).
Some additional limitations should be mentioned. The
true incidence of joint-specific OA will be underestimated
due to practitioners using general codes (e.g. OA), par-
ticularly for patients presenting with multiple affected
joints. Our estimates of knee OA in particular are low by
comparison with other published primary care incidence
rates [24]. We used a stand-alone primary care database
and in other health conditions the importance of linked
secondary care records for complete capture of cases
has been demonstrated [49]. The proportion of cases of
OA diagnosed in secondary care and not recorded in the
CPRD primary care database is not known but in the
Canadian studies, physician claims accounted for
8090% of cases [30] and the general practitioner for
84% of all cases identified from visits to health profes-
sionals [11]. A similar contribution from secondary care
diagnoses to OA prevalence estimates was seen in
Swedish healthcare registry data [26]. Cases diagnosed
as OA in secondary care are nevertheless likely to be
captured within the primary care health record using our
broader definition of clinical OA.T
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Conclusions
Between 1992 and 2013, the age-standardized incidence
of all clinical OA increased while that of diagnosed OA
remained stable or even declined. Amid strong period ef-
fects, cohorts born after the mid-1950s are showing
higher incidence rates of clinical OA than previous gener-
ations at the same age. Prescribed opioid analgesia and
plain radiography appear to be over-used.
Acknowledgements
The authors would like thank Prof. Peter Croft and
Ingemar Petersson for insightful comments on the draft
manuscript. G.P. and K.P.J. would like to thank Public
Health England for their Honorary Academic Consultant
Contracts.
Funding: This research was funded by infrastructure sup-
port funds from North Staffordshire Primary Care
Research Consortium.
Disclosure statement: The authors have declared no
conflicts of interest.
Supplementary data
Supplementary data are available at Rheumatology
Online.
References
1 GBD 2015 DALYs and HALE Collaborators. Global, re-
gional, and national disability-adjusted life-years (DALYs)
for 315 diseases and injuries and healthy life expectancy
(HALE), 1990-2015: a systematic analysis for the Global
Burden of Disease Study 2015. Lancet 2016;388:160358.
2 Pabinger C, Geissler A. Utilization rates of hip arthroplasty
in OECD countries. Osteoarthritis Cartilage
2014;22:73441.
3 Pabinger C, Lothaller H, Geissler A. Utilization rates of
knee-arthroplasty in OECD countries. Osteoarthritis
Cartilage 2015;23:166473.
4 Kurtz SM, Lau E, Ong KL, Katz JN, Bozic KJ. Universal
health insurance coverage in Massachusetts did not
change the trajectory of arthroplasty use or costs. Clin
Orthop Relat Res 2016;474:10908.
5 Culliford DJ, Maskell J, Beard DJ et al. Temporal trends in
hip and knee replacement in the United Kingdom: 1991 to
2006. J Bone Joint Surg Br 2010;92:1305.
6 Nemes S, Rolfson O, W-Dahl A et al. Historical view and
future demand for knee arthroplasty in Sweden. Acta
Orthop 2015;86:42631.
7 National Joint Registry. 12th NJR Report. 2015. http://
www.njrcentre.org.uk/njrcentre/Portals/0/Documents/
England/Reports/12th%20annual%20report/NJR%20
Online%20Annual%20Report%202015.pdf?ver=2015-09-
14-170656-847 (7 July 2017, date last accessed).
8 Hiligsmann M, Cooper C, Arden N et al. Health economics
in the field of osteoarthritis: an expert’s consensus paper
from the European Society for Clinical and Economic
Aspects of Osteoporosis and Osteoarthritis (ESCEO).
Semin Arthritis Rheum 2013;43:30313.
9 Puig-Junoy J, Ruiz Zamora A. Socio-economic costs of
osteoarthritis: a systematic review of cost-of-illness stu-
dies. Semin Arthritis Rheum 2015;44:53141.
10 Cross M, Smith E, Hoy D et al. The global burden of hip
and knee osteoarthritis: estimates from the global burden
of disease 2010 study. Ann Rheum Dis 2014;73:132330.
11 Kopec JA, Rahman MM, Sayre EC et al. Trends in phys-
ician-diagnosed osteoarthritis incidence in an administra-
tive database in British Columbia, Canada, 1996-1997
through 2003-2004. Arthritis Rheum 2008;59:92934.
12 Rahman MM, Cibere J, Goldsmith CH, Anis AH, Kopec JA.
Osteoarthritis incidence and trends in administrative
health records from British Columbia, Canada.
J Rheumatol 2014;41:114754.
13 Yu D, Peat G, Bedson J, Jordan KP. Annual consultation
incidence of osteoarthritis estimated from population-
based health care data in England. Rheumatology
2015;54:205160.
14 Herrett E, Gallagher AM, Bhaskaran K et al. Data Resource
Profile: Clinical Practice Research Datalink (CPRD). Int J
Epidemiol 2015;44:82736.
15 Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ.
Validation and validity of diagnoses in the General Practice
Research Database: a systematic review. Br J Clin
Pharmacol 2010;69:414.
16 Widdifield J, Labrecque J, Lix L et al. Systematic review
and critical appraisal of validation studies to identify
rheumatic diseases in health administrative databases.
Arthritis Care Res 2013;65:1490503.
17 Shrestha S, Dave AJ, Losina E, Katz JN. Diagnostic ac-
curacy of administrative data algorithms in the diagnosis
of osteoarthritis: a systematic review. BMC Med Inform
Decis Mak 2016;16:82.
18 Turkiewicz A, Petersson IF, Bjo¨rk J et al. Current and
future impact of osteoarthritis on health care: a popula-
tion-based study with projections to year 2032.
Osteoarthritis Cartilage 2014;22:182632.
19 Sun J, Gooch K, Svenson LW, Bell NR, Frank C.
Estimating osteoarthritis incidence from population-based
administrative health care databases. Ann Epidemiol
2007;17:516.
20 Kopec JA, Rahman MM, Berthelot JM et al. Descriptive
epidemiology of osteoarthritis in British Columbia,
Canada. J Rheumatol 2007;34:38693.
21 van der Waal JM, Bot SD, Terwee CB et al. The incidences
of and consultation rate for lower extremity complaints in
general practice. Ann Rheum Dis 2006;65:80915.
22 Schers H, Bor H, van den Hoogen H, van Weel C. What
went and what came? Morbidity trends in general practice
from the Netherlands. Eur J Gen Pract 2008;14:1324.
23 van den Dungen C, Hoeymans N, Boshuizen HC et al. The
influence of population characteristics on variation in
general practice based morbidity estimations. BMC Public
Health 2011;11:887.
24 Prieto-Alhambra D, Judge A, Javaid MK et al. Incidence
and risk factors for clinically diagnosed knee, hip and hand
osteoarthritis: influences of age, gender and osteoarthritis
affecting other joints. Ann Rheum Dis 2014;73:165964.
www.rheumatology.oxfordjournals.org 15
Trends in OA incidence between 1992 and 2013 in UK
25 Jordan K, Clarke AM, Symmons DP et al. Measuring dis-
ease prevalence: a comparison of musculoskeletal dis-
ease using four general practice consultation databases.
Br J Gen Pract 2007;57:714.
26 Jordan KP, Jo¨ud A, Bergknut C et al. International com-
parisons of the consultation prevalence of musculoskel-
etal conditions using population-based healthcare data
from England and Sweden. Ann Rheum Dis
2014;73:2128.
27 Brilleman SL, Salisbury C. Comparing measures of multi-
morbidity to predict outcomes in primary care: a cross
sectional study. Fam Pract 2013;30:1728.
28 Bedson J, Belcher J, Martino OI et al. The effectiveness of
national guidance in changing analgesic prescribing in
primary care from 2002 to 2009: an observational data-
base study. Eur J Pain 2013;17:43443.
29 Carstensen B. Age-period-cohort models for the Lexis
diagram. Stat Med 2007;26:301845.
30 Marshall DA, Vanderby S, Barnabe C et al. Estimating the
burden of osteoarthritis to plan for the future. Arthritis Care
Res 2015;67:137986.
31 NICE. 2015. https://www.nice.org.uk/guidance/cg79
(7 July 2017, date last accessed).
32 Medicines and Healthcare Products Regulatory Agency.
2015. https://www.gov.uk/government/publications/cox-
2-selective-inhibitors-and-non-steroidal-anti-inflamma-
tory-drugs-nsaids-cardiovascular-safety/cox-2-selective-
inhibitors-and-non-steroidal-anti-inflammatory-drugs-
nsaids-cardiovascular-safety (7 July 2017, date last
accessed).
33 Newton JN, Briggs AD, Murray CJ et al. Changes in health
in England, with analysis by English regions and areas of
deprivation, 1990-2013: a systematic analysis for the
Global Burden of Disease Study 2013. Lancet
2015;386:225774.
34 National Joint Registry. NJR Reports. http://www.njrre-
ports.org.uk/ (17 November 2016, date last accessed).
35 Allman-Farinelli MA, Chey T, Bauman AE, Gill T, James
WP. Age, period and birth cohort effects on prevalence of
overweight and obesity in Australian adults from 1990 to
2000. Eur J Clin Nutr 2008;62:898907.
36 Reither EN, Hauser RM, Yang Y. Do birth cohorts matter?
Age-period-cohort analyses of the obesity epidemic in the
United States. Soc Sci Med 2009;69:143948.
37 Jiang L, Tian W, Wang Y et al. Body mass index and
susceptibility to knee osteoarthritis: a systematic review
and meta-analysis. Joint Bone Spine 2012;79:2917.
38 Jiang L, Rong J, Wang Y et al. The relationship between
body mass index and hip osteoarthritis: a systematic review
and meta-analysis. Joint Bone Spine 2011;78:1505.
39 Nguyen US, Zhang Y, Zhu Y et al. Increasing prevalence of
knee pain and symptomatic knee osteoarthritis: survey
and cohort data. Ann Intern Med 2011;155:72532.
40 Ruscitto A, Smith BH, Guthrie B. Changes in opioid and
other analgesic use 1995-2010: repeated cross-sectional
analysis of dispensed prescribing for a large geographical
population in Scotland. Eur J Pain 2015;19:5966.
41 Zin CS, Chen LC, Knaggs RD. Total number of prescrip-
tions and number of patients stratified by non-cancer and
cancer pain CPRD 2000-2010. Pharmacoepidemiol Drug
Safe 2012;21:403.
42 Foy R, Leaman B, McCrorie C et al. Prescribed opioids in
primary care: cross-sectional and longitudinal analyses of
influence of patient and practice characteristics. BMJ
Open 2016;6:e010276.
43 Stannard C. Opioids in the UK: what’s the problem? BMJ
2013;347:f5108.
44 Bedson J, Chen Y, Hayward RA et al. Trends in long-term
opioid prescribing in primary care patients with musculo-
skeletal conditions: an observational database study. Pain
2016;157:152531.
45 Melzer D, Tavakoly B, Winder RE et al. Much more
medicine for the oldest old: trends in UK electronic clinical
records. Age Ageing 2015;44:4653.
46 RCR Working Party. Making the Best Use of a Department
of Clinical Radiology: Guidelines for Doctors, 4th edn.
London: The Royal College of Radiologists, 1998.
47 National Collaborating Centre for Chronic Conditions.
Osteoarthritis: National Clinical Guideline for Care and
Management in Adults. London: Royal College of
Physicians, 2008.
48 Zhang W, Doherty M, Peat G et al. EULAR evidence-
based recommendations for the diagnosis of knee
osteoarthritis. Ann Rheum Dis 2010;69:4839.
49 Millett ER, Quint JK, De Stavola BL, Smeeth L, Thomas
SL. Improved incidence estimates from linked vs. stand-
alone electronic health records. J Clin Epidemiol
2016;75:669.
16 www.rheumatology.oxfordjournals.org
Dahai Yu et al.
